

Lupin up on US FDA nod for generic

Shares of Lupin gained 1.6 per cent after the US Food and Drug Administration gave a tentative approval for the generic version of cholesterol drug niacin, a form of vitamin B, on Monday. Analysts say niacin's US sales are \$1.2 billion, of which Lupin can make \$30 million a year. REUTERS

Company .